Endocrine Abstracts

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a clinically heterogenous group. Determining the appropriate selection of therapy and optimal monitoring can be difficult due to their diverse behavior. Furthermore, monitoring or surveillance typically consist of frequent imaging, potentially over decades. Circulating tumor DNA (ctDNA) has shown promise as a minimally invasive approach to disease monitoring and treatment response assessment in a variety o...